On September 16, 2020, GT Biopharma, Inc. (the "Company") reported that it entered into a Securities Purchase Agreement with two purchasers (individually, a "Purchaser," and collectively, the "Purchasers") pursuant to which the Company has issued to the Purchasers Convertible Debentures in an aggregate principal amount of $250,000 (the "Debentures"), which Debentures are convertible into the Company’s common stock (the "Common Stock") at a price of $0.20 per share (Filing, 8-K, GT Biopharma, SEP 16, 2020, View Source [SID1234565479]).

The issuance of the Debentures was made in reliance on the exemption provided by Section 4(a)(2) of the Securities Act of 1933, as amended (the "Securities Act"), for the offer and sale of securities not involving a public offering and Regulation D promulgated under the Securities Act.

The foregoing summaries of the Securities Purchase Agreement, and the Debentures are qualified in their entirety by reference to the full text of the agreements, which are attached hereto as Exhibits 10.1 and 4.1, respectively, and are incorporated herein by reference.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On September 16, 2020 Enlivex Therapeutics Ltd., a clinical-stage immunotherapy company, reported that the China National Intellectual Property Administration (CNIPA) issued a notice of allowance for a new patent application covering ALLOCETRA, the company’s immunotherapy product candidate (Press release, Enlivex Therapeutics, SEP 16, 2020, View Source [SID1234569023]). Upon issuance, the new patent will provide added intellectual property protection, including methods, uses and pharmaceutical compositions. The company expects that this new patent will be issued in China during the fourth quarter of 2020.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

ALLOCETRA has been designed to provide a novel immunotherapy mechanism of action that targets life-threatening clinical indications that are defined as "unmet medical needs", including organ dysfunction and acute multiple organ failure associated with Sepsis and COVID-19, as well as treating solid tumors by modulating such tumors’ microenvironment.

On September 16, 2020 Oasmia Pharmaceutical’s CEO, Dr Francois Martelet reported that it will present at the 20th Annual Biotech in Europe Forum from 21 – 24 September organised by Sachs Associates (Press release, Oasmia, SEP 16, 2020, View Source [SID1234565236]). The presentation will be available on Oasmia Pharmaceutical’s new website from Monday, September 21.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The 20th Annual Biotech in Europe Forum is recognized as the leading international stage for those interested in investing and partnering in the biotech and life science

On September 16, 2020 The Institute of Cancer Research reported that Results from an early-stage trial demonstrate that using a combination of two precision medicines to target hard-to-treat cancers was safe and showed promise in a range of solid tumour types (Press release, The Institute of Cancer Research, SEP 16, 2020, View Source [SID1234565271]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The trial, led by a team at the Institute of Cancer Research (ICR) in London and the Royal Marsden NHS Foundation Trust, combined AstraZeneca/Merck’s PARP inhibitor Lynparza (olaparib) with the investigational medicine capivasertib, an AKT Kinase inhibitor.

The researchers used the drug combination to target two weaknesses in cancer, namely a damaged system for repairing DNA and ‘addiction’ to the AKT molecule which fuels tumour growth.

In the Phase I trial, researchers gave 64 patients with advanced solid tumours, including those with breast cancer, ovarian cancer and prostate cancers, combinations of Lynparza and capivasertib.

The trial found that the drug combination was safe to use and also efficiently hit the specified targets, and showed promise against a variety of advanced cancers, including those that had become resistant to chemotherapy.

According to the ICR, many of the patients who responded to the treatment had mutations in the genes involved in repairing DNA, including the BRCA genes.

"This new clinical trial is a terrific example of how we can now translate scientific discoveries about the biology of cancer cells into innovative new cancer treatments with real benefits for patients," said Professor Paul Workman, Chief Executive of the ICR.

"It’s also an example of the pioneering strategy we have adopted at the ICR of targeting cancer evolution and drug resistance – often through the use of combination treatments to hit multiple targets at once and block off escape routes, just as is done with diseases like HIV," he added.

The trial was funded by AstraZeneca, with the backing of the Cancer Research UK Experimental Cancer Medicine Centre Combinations Alliance.

Following the promising early results, later-stage clinical trials are planned to assess the drug combination’s benefit and to study its effect in patients whose tumours do not have faults in the AKT gene or related to DNA repair.

On September 16, 2020 ERYTECH Pharma (Euronext Paris: ERYP – Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, reported that it will host its second quarter 2020 conference call and webcast on Tuesday, September 22, 2020, at 2:30 PM CEST/8:30 AM EST to discuss operational highlights (Press release, ERYtech Pharma, SEP 16, 2020, View Source,ERYTECH%20to%20Host%20on%20September%2022%2C%202020%20Second%20Quarter,Conference%20Call%20and%20Business%20Update&text=September%2016%2C%202020%2016%3A30,ET%20%7C%20Source%3A%20Erytech%20Pharma%20S.A.&text=ERYTECH%20is%20a%20clinical%2Dstage,of%20cancer%20and%20orphan%20diseases. [SID1234568714]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The call is accessible via the below teleconferencing numbers, followed by the Conference ID#: 8585556#

USA/Canada: +1 (833) 818-6807 France: +33 1 70 80 71 53
International Dial-In Number: +1 (409) 350-3501 United-Kingdom: +44 2031070289
The webcast can be followed live online via the link: View Source

An archived replay of the call will be available for 7 days by dialing + 1 855 859 2056, Conference ID: 8585556#.

An archive of the webcast will be available on ERYTECH’s website, under the "Investors" section at investors.erytech.com